Infectious cell culture supernatant containing HIV-1 subtype B strain HIV-1_JaGA_B_INMI. The strain was obtained after co-culture of patient PBMC with CD8-depleted PBMC from healthy blood donors.
Infectious cell culture supernatant containing HIV-1 subtype F1 strain HIV-1_IoIo_F1_INMI. The strain was obtained after co-culture of patient PBMC with CD8-depleted PBMC from healthy blood donors.
Infectious cell culture supernatant containing HIV-1 subtype CRF12_BF strain HIV-1_DABP_CFR12_BF_INMI. The strain was obtained after co-culture of patient plasma with CD8-depleted PBMC from healthy blood donors.
Infectious cell culture supernatant containing HIV-1 subtype CRF29_BF strain HIV-1_AvFa_CRF29_BF_INMI. The strain was obtained after co-culture of patient PBMC with CD8-depleted PBMC from healthy blood donors.
Infectious cell culture supernatant containing HIV-1 subtype A1 strain HIV-1_RoLu_A1_INMI. The strain was obtained after co-culture of patient plasma with CD8-depleted PBMC from healthy blood donors.
Gp41 recombinant, carrying the "MIF" motif, typical for subtype AE, in the fusion domain of the subtype B prototype NL4-3 - for studying the fusion function
Plasmid contains the entire genome of HIV-1 (NL4-3) with the respective specific mutations in the protease gene. These may confer drug resistance to specific HIV protease inhibitors and have been identified in clinical specimens from individuals with therapeutic failure.
HIV-1 variant, infectious recombinant virus with specific mutations in the RT gene as indicated. These mutations confer resistance to specific HIV RT inhibitors and have been reported for emerging virus in vivo.
HIV-1 variant, infectious recombinant virus with specific mutations in the RT gene as indicated. These mutations confer resistance to specific HIV RT inhibitors and have been reported for emerging virus in vivo.
HIV-1 variant, infectious recombinant virus with specific mutations in the RT gene as indicated. These mutations confer resistance to specific HIV RT inhibitors and have been reported for emerging virus in vivo.
Plasmid contains the entire genome of HIV-1 with specific mutations in the reverse transcriptase gene, which can confer drug resistance to specific HIV-1 inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on reverse transcriptase inhibitors with virologic therapy failure.
Plasmid contains the entire genome of HIV-1 with specific mutations in the reverse transcriptase gene, which can confer drug resistance to specific HIV-1 inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on reverse transcriptase inhibitors with virologic therapy failure.
Plasmid contains the entire genome of HIV-1 with specific mutations in the reverse transcriptase gene, which can confer drug resistance to specific HIV-1 inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on reverse transcriptase inhibitors with virologic therapy failure.
